About
Technology
Issues
FAQ
Links
Official Page
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.